Heresco-Levy U, Brom D, Greenberg D
Ezrath Nashim-Sarah Herzog Memorial Hospital, Jerusalem, Israel.
Isr J Psychiatry Relat Sci. 1993;30(3):164-74.
A "Schizophrenia Prescribing Practices Questionnaire" was developed and employed in order to obtain, directly from treating psychiatrists, information concerning their use of psychotropic medication in schizophrenia. The analysis of data furnished by 56 survey participants working in various institutions and treatment settings pointed to the following main findings: 1) the use of a wide range of antipsychotic (neuroleptic) drug dosages, 2) the use of high potency neuroleptics as the drugs of choice in all phases of treatment, 3) dissimilar dosing with the main high and low potency neuroleptics, 4) dissimilar haloperidol and chlorpromazine dosing in various types of treatment settings, 5) the use of combinations of neuroleptics and prophylaxis with antiparkinsonian drugs by more than 40% of the sample. The results of the survey are discussed in the context of recent research advances and current treatment recommendations.
为了直接从治疗精神科医生那里获取有关他们在精神分裂症治疗中使用精神药物的信息，开发并使用了一份“精神分裂症处方实践调查问卷”。对在不同机构和治疗环境中工作的56名调查参与者提供的数据进行分析后，得出了以下主要结果：1）使用了广泛的抗精神病（神经阻滞剂）药物剂量；2）在治疗的各个阶段都使用高效能神经阻滞剂作为首选药物；3）主要高效能和低效能神经阻滞剂的给药方式不同；4）在不同类型的治疗环境中，氟哌啶醇和氯丙嗪的给药方式不同；5）超过40%的样本使用了神经阻滞剂联合用药以及使用抗帕金森药物进行预防。调查结果将在近期研究进展和当前治疗建议的背景下进行讨论。
